vs
Krystal Biotech, Inc.（KRYS）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Krystal Biotech, Inc.的季度营收约是RE/MAX Holdings, Inc.的1.5倍（$107.1M vs $71.1M），Krystal Biotech, Inc.净利率更高（48.0% vs 2.0%，领先46.0%），Krystal Biotech, Inc.同比增速更快（17.5% vs -1.8%），Krystal Biotech, Inc.自由现金流更多（$75.4M vs $33.5M），过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs -4.7%）
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
KRYS vs RMAX — 直观对比
营收规模更大
KRYS
是对方的1.5倍
$71.1M
营收增速更快
KRYS
高出19.4%
-1.8%
净利率更高
KRYS
高出46.0%
2.0%
自由现金流更多
KRYS
多$41.9M
$33.5M
两年增速更快
KRYS
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $107.1M | $71.1M |
| 净利润 | $51.4M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 41.5% | 13.1% |
| 净利率 | 48.0% | 2.0% |
| 营收同比 | 17.5% | -1.8% |
| 净利润同比 | 13.0% | -75.2% |
| 每股收益（稀释后） | $1.69 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRYSRMAX
| Q4 25 | $107.1M | $71.1M | ||
| Q3 25 | $97.8M | $73.2M | ||
| Q2 25 | $96.0M | $72.8M | ||
| Q1 25 | $88.2M | $74.5M | ||
| Q4 24 | $91.1M | $72.5M | ||
| Q3 24 | $83.8M | $78.5M | ||
| Q2 24 | $70.3M | $78.5M | ||
| Q1 24 | $45.3M | $78.3M |
净利润KRYSRMAX
| Q4 25 | $51.4M | $1.4M | ||
| Q3 25 | $79.4M | $4.0M | ||
| Q2 25 | $38.3M | $4.7M | ||
| Q1 25 | $35.7M | $-2.0M | ||
| Q4 24 | $45.5M | $5.8M | ||
| Q3 24 | $27.2M | $966.0K | ||
| Q2 24 | $15.6M | $3.7M | ||
| Q1 24 | $932.0K | $-3.4M |
营业利润率KRYSRMAX
| Q4 25 | 41.5% | 13.1% | ||
| Q3 25 | 42.3% | 25.0% | ||
| Q2 25 | 40.9% | 19.3% | ||
| Q1 25 | 41.0% | 7.2% | ||
| Q4 24 | 45.4% | 5.9% | ||
| Q3 24 | 26.8% | 19.4% | ||
| Q2 24 | 12.2% | 20.6% | ||
| Q1 24 | -14.8% | 5.8% |
净利率KRYSRMAX
| Q4 25 | 48.0% | 2.0% | ||
| Q3 25 | 81.2% | 5.4% | ||
| Q2 25 | 39.9% | 6.4% | ||
| Q1 25 | 40.5% | -2.6% | ||
| Q4 24 | 49.9% | 8.0% | ||
| Q3 24 | 32.4% | 1.2% | ||
| Q2 24 | 22.2% | 4.7% | ||
| Q1 24 | 2.1% | -4.3% |
每股收益（稀释后）KRYSRMAX
| Q4 25 | $1.69 | — | ||
| Q3 25 | $2.66 | — | ||
| Q2 25 | $1.29 | — | ||
| Q1 25 | $1.20 | — | ||
| Q4 24 | $1.53 | — | ||
| Q3 24 | $0.91 | — | ||
| Q2 24 | $0.53 | — | ||
| Q1 24 | $0.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $496.3M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $1.2B | $452.4M |
| 总资产 | $1.3B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资KRYSRMAX
| Q4 25 | $496.3M | $118.7M | ||
| Q3 25 | $392.6M | $107.5M | ||
| Q2 25 | $353.8M | $94.3M | ||
| Q1 25 | $308.8M | $89.1M | ||
| Q4 24 | $344.9M | $96.6M | ||
| Q3 24 | $374.0M | $83.8M | ||
| Q2 24 | $345.8M | $66.1M | ||
| Q1 24 | $359.0M | $82.1M |
总债务KRYSRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益KRYSRMAX
| Q4 25 | $1.2B | $452.4M | ||
| Q3 25 | $1.1B | $448.1M | ||
| Q2 25 | $1.0B | $442.4M | ||
| Q1 25 | $984.7M | $433.5M | ||
| Q4 24 | $946.4M | $429.5M | ||
| Q3 24 | $885.8M | $423.1M | ||
| Q2 24 | $838.9M | $418.4M | ||
| Q1 24 | $799.2M | $412.0M |
总资产KRYSRMAX
| Q4 25 | $1.3B | $582.5M | ||
| Q3 25 | $1.2B | $582.2M | ||
| Q2 25 | $1.1B | $574.8M | ||
| Q1 25 | $1.1B | $571.4M | ||
| Q4 24 | $1.1B | $581.6M | ||
| Q3 24 | $982.3M | $578.6M | ||
| Q2 24 | $917.7M | $571.4M | ||
| Q1 24 | $853.3M | $566.7M |
负债/权益比KRYSRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.5M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $75.4M | $33.5M |
| 自由现金流率自由现金流/营收 | 70.4% | 47.1% |
| 资本支出强度资本支出/营收 | 2.0% | 10.4% |
| 现金转化率经营现金流/净利润 | 1.51× | 28.39× |
| 过去12个月自由现金流最近4个季度 | $188.9M | $56.8M |
8季度趋势，按日历期对齐
经营现金流KRYSRMAX
| Q4 25 | $77.5M | $40.9M | ||
| Q3 25 | $39.7M | $17.7M | ||
| Q2 25 | $52.7M | $4.6M | ||
| Q1 25 | $31.0M | $5.7M | ||
| Q4 24 | $52.8M | $59.7M | ||
| Q3 24 | $58.9M | $17.6M | ||
| Q2 24 | $-4.2M | $15.9M | ||
| Q1 24 | $15.9M | $9.4M |
自由现金流KRYSRMAX
| Q4 25 | $75.4M | $33.5M | ||
| Q3 25 | $38.0M | $16.4M | ||
| Q2 25 | $50.8M | $2.9M | ||
| Q1 25 | $24.8M | $4.0M | ||
| Q4 24 | $52.0M | $53.0M | ||
| Q3 24 | $57.8M | $16.3M | ||
| Q2 24 | $-5.3M | $14.0M | ||
| Q1 24 | $14.6M | $6.8M |
自由现金流率KRYSRMAX
| Q4 25 | 70.4% | 47.1% | ||
| Q3 25 | 38.8% | 22.4% | ||
| Q2 25 | 52.9% | 4.0% | ||
| Q1 25 | 28.1% | 5.3% | ||
| Q4 24 | 57.1% | 73.2% | ||
| Q3 24 | 69.0% | 20.8% | ||
| Q2 24 | -7.5% | 17.8% | ||
| Q1 24 | 32.3% | 8.6% |
资本支出强度KRYSRMAX
| Q4 25 | 2.0% | 10.4% | ||
| Q3 25 | 1.7% | 1.8% | ||
| Q2 25 | 2.0% | 2.2% | ||
| Q1 25 | 7.0% | 2.3% | ||
| Q4 24 | 0.9% | 9.1% | ||
| Q3 24 | 1.2% | 1.7% | ||
| Q2 24 | 1.6% | 2.4% | ||
| Q1 24 | 2.8% | 3.3% |
现金转化率KRYSRMAX
| Q4 25 | 1.51× | 28.39× | ||
| Q3 25 | 0.50× | 4.45× | ||
| Q2 25 | 1.38× | 0.97× | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 1.16× | 10.28× | ||
| Q3 24 | 2.17× | 18.22× | ||
| Q2 24 | -0.27× | 4.29× | ||
| Q1 24 | 17.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRYS
暂无分部数据
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
